{
    "clinical_study": {
        "@rank": "102480", 
        "arm_group": {
            "arm_group_label": "TUDCA and Doxycycline", 
            "arm_group_type": "Experimental", 
            "description": "TUDCA taken orally, 250 mg three times daily. Doxycycline taken orally, 100 mg twice daily"
        }, 
        "brief_summary": {
            "textblock": "The objective of the study is to determine whether the combination of the bile acid TUDCA,\n      and doxycycline will slow the progression of familial and senile amyloidosis."
        }, 
        "brief_title": "Tolerability and Efficacy of a Combination of Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy", 
        "condition": [
            "Amyloidosis; Heart (Manifestation)", 
            "Senile Cardiac Amyloidosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Amyloidosis", 
                "Cardiomyopathies"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Documented transthyretin cardiac amyloidosis by biopsy and staining using\n             immunohistochemistry or mass spectrometry\n\n          -  Echocardiographic appearance of left ventricular wall thickness of 13mm or more in\n             the absence of hypertensive heart disease\n\n          -  Confirmed ATTR or SSA by genetic testing\n\n          -  Age 18-90\n\n          -  Male or non-pregnant, non-lactating females\n\n          -  Willingness to return to the treatment center for follow-up\n\n        Exclusion Criteria:\n\n          -  Prior liver transplantation or liver transplantation anticipated in less than 6\n             months\n\n          -  Alanine Transaminase and/or Aspartate Transaminase \u22652 x upper normal limit (UNL)\n\n          -  Alkaline Phosphatase \u22652 x UNL\n\n          -  Creatinine clearance <20 mL/min\n\n          -  Any other lab values that in the opinion of the investigator might place the subject\n             at unacceptable risk for participation in the study\n\n          -  History of poor compliance\n\n          -  History of hypersensitivity to any of the ingredients of the study therapies\n\n          -  Any investigational drug within 4 weeks prior to study entry or during the study\n\n          -  Current use of diflunisal for therapy of amyloidosis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01855360", 
            "org_study_id": "BWHAMY1"
        }, 
        "intervention": {
            "arm_group_label": "TUDCA and Doxycycline", 
            "intervention_name": "Tauroursodeoxycholic Acid and Doxycycline", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Doxycycline", 
                "Doxycycline hyclate", 
                "Tauroursodeoxycholic acid", 
                "Taurochenodeoxycholic Acid"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "amyloid", 
            "amyloidosis", 
            "cardiac amyloidosis", 
            "senile amyloidosis", 
            "familial amyloidosis", 
            "transthyretin amyloidosis"
        ], 
        "lastchanged_date": "November 19, 2013", 
        "location": {
            "contact": {
                "email": "rfalk@partners.org", 
                "last_name": "Rodney H Falk, MD", 
                "phone": "617-421-6094"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02115"
                }, 
                "name": "Brigham and Women's Hospital/ Harvard Vanguard Medical Associates"
            }, 
            "investigator": {
                "last_name": "Rodney H Falk, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An 18 Month, Open Label Study of the Tolerability and Efficacy of a Combination of Doxycycline and Tauroursodeoxycholic Acid (TUDCA) in Patients With Transthyretin Amyloid Cardiomyopathy.", 
        "overall_contact": {
            "email": "rfalk@partners.org", 
            "last_name": "Rodney H Falk, MD", 
            "phone": "617 421 6094"
        }, 
        "overall_official": {
            "affiliation": "Brigham and Women's Hospital, Boston MA", 
            "last_name": "Rodney H Falk, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Outcome measure, namely changes in longitudinal echocardiographic strain, will be compared to previously determined changes derived from a cohort of patients with TTR cardiac amyloidosis who were not receiving specific therapy for amyloid deposition.", 
            "measure": "The rate of progression of transthyretin cardiac amyloidosis, as measured by changes in strain echocardiography, in a group of patients taking a combination of doxycycline and TUDCA.", 
            "safety_issue": "No", 
            "time_frame": "Time Frame: * (FDAAA)  outcome measure is assessed every 6 months by serial echocardiography, with final measurement 18 months after enrollment."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01855360"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Brigham and Women's Hospital", 
            "investigator_full_name": "Rodney H. Falk, MD", 
            "investigator_title": "Director, Brigham and Women's Hospital Cardiac Amyloidosis Program", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Measurements of kidney function (BUN and creatinine) and blood counts will be done every 3 months.", 
                "measure": "Number of patients with adverse events to the medications over the period of therapy (18 months)", 
                "safety_issue": "Yes", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "To evaluate general and health related quality of life (QoL) in SSA and ATTR subjects.", 
                "safety_issue": "No", 
                "time_frame": "Measurements made every 6 months for 18 months."
            }
        ], 
        "source": "Brigham and Women's Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Brigham and Women's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}